E.g., 06/10/2021
E.g., 06/10/2021

NucliSens® miniMAG™, bioMérieux’s next generation nucleic acid extraction platform is now available as CE-IVD approved platform

25 March, 2005

bioMérieux announces the introduction of the NucliSens miniMAG and NucliSens Magnetic Extraction Reagents as CE-IVD marked products. A major actor in the field of in vitro diagnostics (IVD), bioMérieux thereby reinforces its commitment to quality and fulfilment of the most stringent regulatory requirements.

Chinese Academy of Medical Sciences and bioMerieux join resources to fight emerging pathogens

11 March, 2005

The Chinese Academy of Medical Sciences and bioMérieux announce that they have signed a strategic teaming agreement, aiming at initiating R&D projects in the fields of emerging pathogens. The aim of the project, signed on March 10th, is the creation of a joint Research Lab in Beijing, interacting with Chinese Academy of Medical Sciences.

B·R·A·H·M·S AG and bioMérieux SA sign a non-exclusive agreement on the use of Procalcitonin

01 March, 2005

B·R·A·H·M·S AG and bioMérieux SA have announced the signature of a non-exclusive agreement on the use of Procalcitonin as a diagnostic marker for severe bacterial infections

bioMérieux launches VITEK® 2 Compact to complete its VITEK 2 range

06 January, 2005

A world leader in the field of in vitro diagnostics, bioMérieux SA (Euronext: FR0010096479 – BIM) completes its VITEK® 2 range of automated microbial identification and susceptibility testing systems through the launch of VITEK 2 Compact. VITEK 2 Compact is powered by the Advanced Expert System (AES™) software, which validates and interprets susceptibility test results, and detects antibiotic resistance mechanisms.

bioMérieux acquires an option to license Applied NeuroSolutions’ Technology to diagnose Alzheimer’s disease

15 December, 2004

bioMérieux SA (Euronext: FR0010096479 – BIM) , announces today that it signed a non-exclusive agreement with Applied Neurosolutions granting bioMérieux SA an option to assess Applied Neurosolutions’ technology for the diagnosis of Alzheimer’s disease.

bioMérieux reveals VIDIA, its new automated immunoanalyser, in Paris at the Journées Internationales de Biologie

05 November, 2004

A major player in the in vitro diagnostics marketplace, bioMérieux announces the first official presentation of its new fully automated immunoanalyser, VIDIA®. The system will be presented to healthcare professionals at the Journées Internationales de Biologie held in Paris from November 4 - 6, 2004.

bioMérieux to assess potential of PlasmAcute® Technology for tuberculosis testing

25 October, 2004

Novel Diagnostics ASA and bioMérieux announced today that they have signed an agreement that gives bioMérieux access to patented PlasmAcute® acute phase antibody detection technology for use in the field of tuberculosis detection.

bioMérieux signs New Agreements with Gen-Probe

10 October, 2004

bioMérieux receives a $ 1 million license fee for access to its markers for blood clotting disorders. bioMérieux to give Gen-Probe an option for the access to bioMérieux NUCLISENS EASYQ® platform. bioMérieux Gains Access to ribosomal RNA markers to support its future growth in molecular biology.

bioMérieux innovates further in the fight against AIDS

27 September, 2004

A major player in the field of in vitro diagnostics, bioMérieux confirms its constant commitment to the fight against AIDS with the launch of two new advanced 4th generation tests for HIV screening. VIDAS® HIV DUO ULTRA and VIDAS HIV DUO QUICK, developed for use on the automated VIDAS immunoanalysis system, are ultra-sensitive tests, providing even earlier detection of HIV infection.

Pioneering diagnostics